Prosecution Insights
Last updated: November 19, 2026
Application No. 18/355,061

IMPLANTS AND METHODS FOR MASTOPEXY

Final Rejection §DOUBLEPATENT
Filed
Jul 19, 2023
Priority
Mar 09, 2011 — provisional 61/451,103 +7 more
Examiner
GHERBI, SUZETTE JAIME J
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Tepha Inc.
OA Round
2 (Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1201 granted / 1410 resolved
+15.2% vs TC avg
Moderate +9% lift
Without
With
+8.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
31 currently pending
Career history
1443
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
39.6%
-0.4% vs TC avg
§102
25.1%
-14.9% vs TC avg
§112
11.2%
-28.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1410 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Response to Arguments Applicant's arguments filed 5/21/26 have been fully considered but they are not fully persuasive. The applicant response/argument with respect to the 102 rejection of claims 22, 24 and 27-28 is persuasive, however the double patenting rejection is still deemed proper. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 4. Claims 22-23 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 8,858,629 (hereafter '629). Although the claims at issue are not identical, they are not patentably distinct from each other. Current claim 22 recites: "22. A method for elevating a lower pole of a breast, comprising: providing a lower pole support and a positioning tool, loading a tubular distal section of the positioning tool with the lower pole support, delivering at least a portion of the lower pole support through an access incision with the positioning tool, and anchoring the lower pole support around breast parenchyma to retain the breast in place." Pat. '629 claim 1 recites" "1. A mastopexy system, comprising: a lower pole support comprising a body region and a plurality of upper and lower straps, and wherein each of said upper and lower straps being a continuous extension and integral with the body region of said lower pole support, and a first positioning tool comprising a tubular distal section loaded with the lower pole support, wherein the first positioning tool facilitates placement of the lower pole support within a breast through an incision, and wherein the lower pole support holds the breast in place when anchored by the upper and lower straps to a support tissue structure and the body region is around breast parenchyma and wherein the lower pole support is positioned within the tubular distal section of the positioning tool." It is obvious to one having ordinary skill in the art that current method claims as currently recited are fully recited as functional intended use claims within the patent the patent. It is also obvious that "facilitating placement" is equivalent to "delivering". 5. Regarding claim 23, pat. 629 does not specifically state that the withdrawing the positioning tool through the access incision. It would have been obvious to remove the tool through the incision because the incision is where access is initially gained and the tool does not remain in the body. 6. Claim 24 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 8,858,629 (hereafter '629) in view of Moses et al. claims 1-22 of U.S. Pat. 10,765,507 (hereafter '507) has been disclosed however does not recite positioning the pole support within a body pocket formed through the access incision. 7. Regarding claim 25, pat. '629 does not recite delivering the lower pole support through a periareolar incision. Pat. '507 claim 1 and 16 recite that at least one access incision is made in the vicinity of the NAR (nipple areola complex). It is obvious to one having skill in the art that this is equivalent to inserting through a periareolar incision. 8. Regarding claim 26, see pat. '629 claims 2-5. Regarding claims 27, see pat. '629 claim 1. Regarding claim 28 see claims 1 which recites attaching to tissue. Regarding claim 29, see pat. '629 last sentence of claim 1. 9. Regarding claim 30, see pat. '629 claim 10. Regarding claim 31, see pat. '629 claim 8. 11. Claims 32, 48-49 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 10,765,507 (hereafter '507) in view of U.S. Pat. 8,858,629 (hereafter '629). Although the claims at issue are not identical, they are not patentably distinct from each other. 12. Current claim 32 recites: "32. A minimally invasive method for placing a device to lift a breast and NAC of a patient from a first position to a second position comprising: making a first incision in a side of the breast; creating a subcutaneous body pocket in an inferior portion of the breast; advancing a lower pole support positioning tool though the first incision and into the body pocket; deploying a lower pole support in the body pocket; manipulating the body of the lower pole support to span the body pocket; manipulating tissue of the breast and the NAC to the second position; and attaching the lower pole support to supportive tissue to secure the breast and the NAC in the second position." Pat. '507 claims 1 and 17 recites: "1. A method for elevating a lower pole of a breast from a first position to an elevated target position, the breast comprising a superficial, inferior half, and a NAC, the method comprising the steps of: creating at least one access incision in the vicinity of the NAC; dissecting in the superficial, inferior half of the breast through the at least one incision to create a space; positioning a lower pole support into the space; adjusting the position of the breast from the first position to the elevated target position; and affixing the lower pole support after the breast is positioned in the elevated target position and wherein the affixing is performed by securing a plurality of straps radially extending from a body of the lower pole support to supportive tissue." "17. The method of claim 1, wherein the dissecting the space comprises creating a triangular shaped pocket." However '507 does not recite the positioning tool. Pat. '629 claims recite the use of a positioning tool (see claims 1 and 7-9). Pat. '623 also recites that the pole support may have a canoe shape. It would have been obvious to one having ordinary skill in the art to utilize a "tool" for positioning the support member in order to ensure accurate placement of the implant. It is further obvious that the "second" position as claimed can equate to the limitation of "a first position to an elevated position" where the elevated position is the "second position". It further would have been obvious to have the implant "span" the lower pole because of it being claimed to have a canoe shaped. 13. Regarding claims 48-49, pat. '507 does not specifically state "wherein the step of manipulating the breast and NAC to the second position is performed by manipulating the mesh". It is obvious that this step is performed because pat. '507 claim 20 states cutting and folding a mesh structure and positioning it into the space. 14. Regarding claims -5453 see claims 1 and 11 of pat. ‘507. Allowable Subject Matter 14. Claims 33-47, 50-52 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. 15. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art is considered to be Shfaram 2006/0167338, however Shfaram does not disclose the methods of: "A minimally invasive method for placing a device to lift a breast and NAC of a patient from a first position to a second position comprising: making a first incision in a side of the breast; creating a subcutaneous body pocket in an inferior portion of the breast; advancing a lower pole support positioning tool though the first incision and into the body pocket; deploying a lower pole support in the body pocket; manipulating the body of the lower pole support to span the body pocket; manipulating tissue of the breast and the NAC to the second position; and attaching the lower pole support to supportive tissue to secure the breast and the NAC in the second position then creating a second incision on the side of the breast opposite to the first incision; and wherein the deploying step comprises deploying a lower pole support in the body pocket from the lower pole support positioning tool, the lower pole support comprising a body and plurality of upper straps and a plurality of lower straps. Shfaram further does not disclose the step of removing skin above the NAC to for the second position for the NAC in conjunction with the limitations of claim 32. Shfaram further does not disclose the steps of "creating at least one channel pocket extending from the body pocket to the support tissue, and wherein manipulating the upper straps comprises manipulating at least one upper strap through the channel pocket to the support tissue. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzette Gherbi whose telephone number is (571)272- 4751. The examiner can normally be reached on Monday-Friday 7:00am-3:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http:/Avww.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Melanie Tyson can be reached on 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https:/Awww.uspto.gov/patents/apply/patent- center for more information about Patent Center and https:/Awww.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197. /SUZETTE J GHERBI/Primary Examiner, Art Unit 3774 August 17, 2026
Read full office action

Prosecution Timeline

Jul 19, 2023
Application Filed
Feb 24, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Apr 30, 2026
Examiner Interview Summary
Apr 30, 2026
Applicant Interview (Telephonic)
May 21, 2026
Response Filed
Aug 19, 2026
Final Rejection mailed — §DOUBLEPATENT
Nov 17, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797188
PROSTHETIC HEART VALVE FOR MITIGATING STAGNATION
3y 7m to grant Granted Nov 17, 2026
Patent 12788557
PROSTHETIC VALVES AND METHODS OF MAKING
3y 8m to grant Granted Nov 10, 2026
Patent 12788573
IMPLANT PEG WITH MULTIPLE COMPONENTS
3y 5m to grant Granted Nov 10, 2026
Patent 12788550
DEVICES FOR PROVIDING TISSUE SUPPORT DURING BREAST RECONSTRUCTION, AND SYSTEMS AND METHODS THEREOF
1y 4m to grant Granted Nov 10, 2026
Patent 12773312
PROSTHETIC HEART VALVE LEAFLET ASSEMBLIES AND METHODS
3y 7m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
94%
With Interview (+8.7%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1410 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month